---
title: "Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291290809.md"
description: "Artelo Biosciences presented evidence at ICRS 2026 linking its FABP5 inhibitor platform to lipid signaling. A multi-omics study identified linoleic acid as a key fatty acid regulated by ART26.12, highlighting its role in cellular functions and the protein's impact on linoleic acid levels."
datetime: "2026-06-30T12:59:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291290809.md)
  - [en](https://longbridge.com/en/news/291290809.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291290809.md)
---

# Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026

A recent study using multi-omics analyses has pinpointed linoleic acid as a vital fatty acid that is influenced by the regulator protein ART26.12. This research delved into various biological data sets to reveal the importance of linoleic acid, highlighting its critical role in cellular functions. The findings underscore the significance of ART26.12 in modulating the levels and effects of linoleic acid within the body. This study sheds light on the relationship between ART26.12 and linoleic acid, providing valuable insights into their interconnected functions.

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [Artelo Biosciences says Phase 1 study shows FABP5 inhibitor ART26.12 is well tolerated, with linear pharmacokinetics](https://longbridge.com/en/news/291147934.md)
- [PCSA: Acquisition brings a novel BTK inhibitor and $200M funding to advance three parallel clinical programs](https://longbridge.com/en/news/294217251.md)
- [Clinuvel benchmarks vitiligo market as JAK inhibitor efficacy challenges NB-UVB standard of care](https://longbridge.com/en/news/294281005.md)
- [The Protein Gold Rush Is Here—So Why Are Protein Stocks Crashing?](https://longbridge.com/en/news/293848698.md)
- [Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis](https://longbridge.com/en/news/293951940.md)